# Pharaoh Neuro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharaoh-neuro

- Industry: Medical Devices & Equipment
- Headquarters: Minneapolis, US
- Website: www.pharaohneuro.com
- Total disclosed funding: $20M
- Latest round: Series A (Feb 20, 2026)
- Investors on record: 4

## About

Pharaoh Neuro, Inc. is a US-based company focused on developing advanced medical technologies that enhance neurocritical care through innovative products, particularly the Neurapheresis™ platform.Pharaoh Neuro, Inc. specializes in neurocritical care technologies and has its headquarters in Minneapolis, US. The company has recently secured funding through a Series A round, raising USD 20.00 mn led by Arboretum Ventures, with participation from Hatteras Venture Partners, IAG Capital Partners, and Laerdal Million Lives Fund. The CEO and founder information is not detailed in the current data.Pharaoh Neuro specializes in pioneering medical technologies aimed at enhancing neurocritical care through its flagship product, the Neurapheresis™ platform. This innovative system is designed for the precision management of cerebrospinal fluid (CSF), addressing critical medical needs in patients with neurocritical conditions such as aneurysmal subarachnoid hemorrhage. The Neurapheresis™ technology focuses on stabilizing CSF balance, essential for maintaining brain health. The primary users of these products include neurocritical care units in hospitals, neurosurgeons, and other healthcare professionals specialized in treating severe neurological disorders. The company is actively looking to expand its reach in North America and Europe, with products being utilized in advanced medical facilities emphasizing neurological health care.Pharaoh Neuro has recently secured USD 20.00 mn in Series A funding, indicating a structured approach to revenue generation through strategic partnerships and investments. The firm's business model revolves around direct engagement with healthcare institutions and professionals, focusing on implementation and utilization of its Neurapheresis™ platform. Revenue generation may involve ongoing service agreements or partnerships that facilitate continuous support and integration of the technology within existing neurocritical care systems, primarily derived from the sales of its flagship Neurapheresis™ platform.In February 2026, Pharaoh Neuro, Inc. raised USD 20.00 mn in Series A funding to support the development and regulatory clearance of its Neurapheresis cerebrospinal fluid management system and to reintroduce its MindsEye cranial access device in the U.S. market. The company aims to expand into North America and Europe, leveraging this funding to enhance its product offerings and market presence.

## Funding rounds

- Series A, Feb 20, 2026, $20M — Hatteras Venture Partners, Arboretum Ventures, IAG Capital Partners, Laerdal Million Lives Fund

## Investors

- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Series A
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A
- IAG Capital Partners (https://capitalatlas.ai/funds/iag-capital-partners) — Series A
- Laerdal Million Lives Fund (https://capitalatlas.ai/funds/laerdal-million-lives-fund) — Series A